We were the first certified pediatric center in Florida to offer groundbreaking CAR T-cell therapy for children with acute lymphoblastic leukemia. Learn more about CAR T-cell therapy in the Center for Adoptive Cellular Therapy at Johns Hopkins All Children’s.
Children with certain cancers that are resistant to chemotherapy or recur multiple times may benefit from adoptive cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy at the Center for Adoptive Cellular Therapy at Johns Hopkins All Children’s Hospital in St. Petersburg, Florida.
Why Choose Johns Hopkins All Children’s
Johns Hopkins All Children’s was the first certified pediatric center in Florida to offer CAR T-cell therapy and is one of the few pediatric programs currently offering this therapy. We have performed the most infusions of CAR T-cells in pediatric patients in the state.
John Hopkins All Children's met nationally established selection criteria by demonstrating expertise in delivering quality specialty care, safely and effectively, and was awarded the Blue Distinction® for Cellular Immunotherapy CAR-T designation.
The Center for Adoptive Cellular Therapy has been established to improve the health of children with cancer through the clinical application of adoptive cellular therapies, excellent clinical care and translational research. Patients treated with CAR T-cell therapies are monitored closely by our experienced team.
What Is CAR T-cell Therapy?
CAR T-cell therapy is a unique and highly personalized treatment that uses the body’s own immune system to fight cancer. This is called immunotherapy.
The immune system contains T-cells, a type of white blood cell that is one of the body’s strongest lines of defense. T-cells are capable of fighting infections and also detecting and eliminating cancerous cells. During CAR T-cell therapy, T-cells are removed from a blood sample, genetically modified to enhance their cancer-fighting abilities, and then added back into the body. Once in the bloodstream, the modified cells attack and destroy cancer cells. CAR T-cell therapy is recognized as a breakthrough in cancer treatment. It can be a lifesaving option for patients for whom chemotherapy has not resulted in cure.
Who is eligible for CAR T-cell therapy?
Patients up to 21 years of age in their second or greater relapse of B-acute lymphoblastic leukemia, or those with disease that is resistant to chemotherapy, are eligible for CAR T-cell therapy at Johns Hopkins All Children’s.
How CAR T-cell Therapy Works
Receiving CAR T-cell therapy is a multistep process. Your child’s care team will explain it thoroughly so you know what to expect at each stage. These steps include:
- Your child’s white blood cells are removed from a blood sample in a process called leukapheresis, and then sent to a laboratory.
- Scientists separate the T-cells from the rest of the white blood cells and add a gene for a chimeric antigen receptor (CAR) to the T-cells. This transforms them into CAR T-cells. The CAR allows T-cells to recognize and eliminate cancer cells.
- The body requires millions of CAR T-cells to treat cancer. Growing these new cells in the lab takes a few weeks, during which time your child may receive low-dose chemotherapy.
- When the CAR T-cells are ready, your child’s doctor schedules the infusion. A short, typically four-day, course of chemotherapy is used to prepare your child for the CAR T-cell infusion. The CAR T-cells are given back in one dose in a process similar to a blood transfusion.
- The CAR T-cells begin to multiply and target cancer cells. They can remain in the body for months, or even years, seeking out and eliminating any remaining cancer cells.
Possible Side Effects
CAR T-cell therapy is associated with side effects related to the activation of the immune system. Possible side effects from CAR T-cell therapy are generally temporary and include:
- Cytokine release syndrome: CAR T-cells release signals called cytokines that activate the immune system. This can result in side effects including flu-like symptoms, fevers, fatigue and in more severe cases, low blood pressure or difficulty breathing.
- Neurologic toxicity: Patients may experience confusion, difficulty speaking, or stupor, among other symptoms. These symptoms typically resolve.
There are effective therapies to help patients experiencing these side effects including steroids and a cytokine-blocking medicine called tocilizumab. Our team is highly experienced in treating side effects of CAR T-cell therapy.
Other Adoptive Cellular Therapies
Virus-Specific T-cell Therapy
In patients with decreased immune function following a stem cell transplant or due to immunosuppressive medications, viral infections can be difficult to treat and can cause significant harm, even with the use of antiviral therapies. As one of the major functions of T-cells is to kill viruses, we can use the infusion of allogeneic (from someone else) T-cells to recognize and kill viruses that have persisted despite anti-viral medications. We are participating in a multi-institutional clinical trial using virus-specific T-cells to treat viral infections.
These organizations provide additional information and resources for families:
For more information about CAR T-cell therapy, call us at the phone number below. We serve families throughout the greater Tampa Bay area and beyond.
The Center for Adoptive Cellular Therapy is supported by a generous grant through the V-Foundation.